MM Restructuring IB

Hi all, I just wanted to ask what a restructuring group in a middle market IB group (RJ/Blair/Stephens) is like compared to EB. Haven't found any info on that in the search.

Exits? WLB? Difference vs your typical EB group?

Mix of Debtor/Creditor mandates. 

9 Comments
 

There are huge differences between different MM firms that have "restructuring" practices. Fastest way to tell, other than asking the people that work there, is to a) do a Debtwire search (or have a friend do it for you if you don't have access) and b) look at the background of senior people.

A lot of MM firms label what is essentially a capital raise for stressed businesses practice as "restructuring" or "special situations". Others have strong practices in true restructuring where their sector strengths lie (e.g. PJ Solomon and consumer). If you see an ex-Miller guy with several high profile deals listed on his profile leading the group, chances are the MM is in the latter bucket. 

 

Have actually seen (via Linkedin) quite a few MM banks w/ RX groups (namely Oppenheimer, RJ, & Baird) hiring ex RX consultants/CROs more frequently. My thought process is bc RX industry is nuanced and there’s not a plethora of Sr. talent to pull from, having a seasoned RX professional that financially & operationally ran multiple companies through Ch. 11 process is a net benefit for deal flow, and there may be some overlap in responsibilities (especially on the lender-side advisory space, which are majority of mandates those MMs are competing for). Would say that ex-CROs are highly respected in the space, but a bank hiring them likely means its young team looking to grow by landing its first few headline deals. Feel free to throw in any thoughts on that, but that’s how I would view it.

 
Most Helpful

Short answer is it varies a ton. Of the firms you mentioned, RJ does not do a lot of true rx work, Stephens had recently acquired a TX boutique, Blackhill, which was fairly legit, however I believe that entire team has left Stephens already, and I don’t think Blair does any rx work at all (have never seen them on any meaningful mandates and fairly certain they don’t have a dedicated rx group).

Of the stronger MM groups that do a lot of true restructurings (vs. just private debt placements), the work experience would be relatively comparable to the major “EB” groups, at least from a technical standpoint. Exits, anecdotally, skew more to private credit/credit HF roles or A2A promotes vs. PE, but generally would think you’d have a lot of optionality if you want it given the rigor of the work.

Frankly though, the MM rx space is largely dominated by many of the same “EB” banks that do the larger deals. This is especially the case in times like the current when there isn’t much rx work to go around and those guys move downstream.

 

Earum in recusandae consequatur aut accusamus vel. Recusandae ipsum assumenda pariatur doloremque perspiciatis. Quae inventore necessitatibus nemo id consectetur. Aut voluptas minus vitae amet adipisci amet nostrum.

Pariatur deleniti nihil quas adipisci neque eius. Repellendus cumque libero ipsam laborum veniam ratione veritatis quis. Optio qui et maxime quos commodi est quia. Labore dolor quo atque ipsum culpa assumenda consequatur nihil. At unde veritatis dicta et molestiae.

Consequatur distinctio nisi id aut molestiae non. Id velit quasi et reiciendis illum et. Perspiciatis vel magnam voluptas molestiae tempora saepe officia.

Expedita sed corporis neque quod nam vero maxime. Quod rerum doloremque impedit optio alias esse. Occaecati id ipsa vel et dolorum et veritatis. Quidem iure est est qui. Enim nulla fuga quos harum placeat.

Career Advancement Opportunities

June 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.3%
  • Guggenheim Partners 01 97.7%
  • Morgan Stanley 07 97.1%

Overall Employee Satisfaction

June 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Morgan Stanley 02 98.8%
  • Evercore 01 98.3%
  • BMO Capital Markets 12 97.7%
  • Banco Santander 01 97.1%

Professional Growth Opportunities

June 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 05 98.3%
  • JPMorgan No 97.7%
  • Goldman Sachs 02 97.1%

Total Avg Compensation

June 2026 Investment Banking

  • Vice President (14) $434
  • Associates (44) $258
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (13) $156
  • 1st Year Analyst (79) $150
  • Intern/Summer Analyst (73) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”